CAR T cell News and Research

RSS

Multiple myeloma mortality rates decline with advances in targeted therapies

A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023."

29 Apr 2026

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

Results of the single-center, phase 2 CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate Chimeric Antigen Receptor (CAR) T-cell therapy in patients with high-risk smoldering multiple myeloma, showed that all 20 patients were negative for minimal residual disease (MRD) within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up, and none experienced high-grade side effects, according to results presented at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.

21 Apr 2026

Single CAR T infusion shows strong response in smoldering multiple myeloma patients

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

20 Apr 2026

State-run insurance plans for foster kids leave some of them without doctors

Ollie Super has moved in and out of cancer treatment since she was diagnosed with neuroblastoma as a toddler in foster care. Now 8, the second grader is dealing with it again. Her cancer came back late last year.

2 Apr 2026

Next-generation CAR T therapy offers hope but faces clinical challenges

A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment."

25 Feb 2026

Optimization of CAR T cells to destroy solid tumors

A team led by LMU physician Sebastian Kobold has found a way to allow the body's immune system to destroy solid tumors.

16 Feb 2026

FDA label update expands CAR T access for primary CNS lymphoma

Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system lymphoma, a rare and aggressive lymphoma of the brain and spinal cord.

9 Feb 2026

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in helping children and adults fight a rare and aggressive form of blood cancer called T-cell acute lymphoblastic leukemia (T-ALL).

8 Dec 2025

Combination therapy may boost survival for people with aggressive lymphoma

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may sharply boost one-year progression-free survival for people with aggressive lymphoma.

8 Dec 2025

Lymphocyte levels help predict outcomes after CAR T-cell therapy in non-Hodgkin lymphoma

Measuring the lymphocytes - white blood cells that fight infection - in a patient's blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to research from physicians at Fox Chase Cancer Center and Temple Health.

8 Dec 2025

Breakthrough immunotherapy approved for treatment of adults with aggressive blood cancer

Adult patients with an aggressive form of leukemia will be able to receive a breakthrough immunotherapy, which was invented by UCL researchers, on the NHS within weeks following approval for use by the National Institute for Health and Care Excellence (NICE).

27 Nov 2025

Longest survival in the world reported to date for multiple myeloma patients

Berenson Cancer Center published survival data analyzed by the Institute for Myeloma & Bone Cancer Research of 175 consecutive and unselected patients with multiple myeloma in the journal Haematologica.

19 Nov 2025

UCI Health launches clinical trial to test investigational cell therapy for lupus

UCI Health has opened a clinical trial to test an investigational cell therapy for lupus with the potential to give patients long-term remission of symptoms.

17 Nov 2025

Lymphoma resistance mechanisms and future therapies

A new review was published in Volume 12 of Oncoscience on October 13, 2025, titled "Targeted therapies and resistance mechanisms in lymphoma: Current landscape and emerging solutions."

13 Nov 2025

Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities

For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms — pain in her spine and hips, nausea, exhaustion, thirst, and frequent urination.

31 Oct 2025

Study explores how losing the Y chromosome fuels bladder cancer aggressiveness

University of Arizona Cancer Center researchers will study the potential effects of the loss of the Y chromosome in the development and progression of bladder cancer thanks to a grant of up to $6.5 million over seven years from the National Cancer Institute.

14 Oct 2025

The 15th AACR cancer progress report highlights scientific advances

The American Association for Cancer Research (AACR) released the 15th edition of its annual Cancer Progress Report. A cornerstone of the AACR's educational and advocacy efforts, this comprehensive report provides the latest statistics on cancer incidence, mortality, and survivorship and highlights how federal investments in basic, translational, and clinical cancer research and cancer-related population sciences have led to impressive scientific advances that are improving health and saving lives.

17 Sep 2025

CAR T cell News and Research

Multiple myeloma mortality rates decline with advances in targeted therapies

CAR-PRISM trial reports promising results in high-risk smoldering multiple myeloma

Single CAR T infusion shows strong response in smoldering multiple myeloma patients

State-run insurance plans for foster kids leave some of them without doctors

Next-generation CAR T therapy offers hope but faces clinical challenges

Optimization of CAR T cells to destroy solid tumors

FDA label update expands CAR T access for primary CNS lymphoma

Genome-edited immune cell therapy shows promise for treating aggressive blood cancer

Combination therapy may boost survival for people with aggressive lymphoma

Lymphocyte levels help predict outcomes after CAR T-cell therapy in non-Hodgkin lymphoma

Breakthrough immunotherapy approved for treatment of adults with aggressive blood cancer

Longest survival in the world reported to date for multiple myeloma patients

UCI Health launches clinical trial to test investigational cell therapy for lupus

Lymphoma resistance mechanisms and future therapies

Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities

Study explores how losing the Y chromosome fuels bladder cancer aggressiveness

The 15th AACR cancer progress report highlights scientific advances

SwRI and UT San Antonio advance biosensor coating to streamline production of immunotherapies

New AI model can identify treatments that reverse disease states in cells

Leukemia-on-a-chip offers breakthrough in personalized cancer treatment

Event guide: 10th CAR-TCR Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News